Nucleo forte capsulas code#

FORTE provides an organism with the phosphatic groups necessary for association of monosaccharides with Keraminums for forming of nervous covers, and the fosfatidny acids making sphingomyelin and glycerophospholipids – the main components of a myelin cover. Thus, association of action of CMF and UTF promotes regeneration of a myelin cover, the correct carrying out nervous excitement and restoration of a muscular trophicity. It results in the intensive metabolic activity promoting, in turn, process of regeneration of a myelin cover, regulating demyelination at peripheral nervous damages. Generally, CMF and UTF take part in synthesis of phospholipids and glycolipids which, generally make a myelin cover and other nervous structures. Besides, he acts as a power source in the course of reduction of muscles. UTF works as a coenzyme in synthesis of glycolipids, neuronalny structures and a myelin cover, supplementing action of CMF. CMF is also a predecessor of nucleic acids (DNA and RNA) which, in turn, are basic elements of cellular metabolism (for example, in proteinaceous synthesis). Nukleo’s pharmacodynamics of CMF Forte contains a number of nucleotides: cytidine monophosphate (CMF), uridine triphosphate (UTF) which widely use for treatment of diseases PNS (peripheral nervous system).įrom the biochemical point of view, action of these two components can be described as follows: CMF takes part in synthesis of a complex of lipids which form a neuronalny membrane, mainly sphingomyelin the main component of a myelin cover. These results indicate that in blood less fast metabolism of uracil in the presence of a tsitozin who was formed of the initial accepted CMF connection was observed. Therefore tsitozin, generally turned into uracil. The CMF connection quickly turned in tsitozin, uracil and, at least, one more polar radioactive fraction. fast transformation through uracil to, at least, one more polar radioactive fraction. The same way of metabolism was found in UMF and UTF, i.e. Then radioactivity was quickly removed with the corresponding elimination half-life of 1.2 and 5.0 hours. Then radioactivity was quickly removed with the corresponding elimination half-life 1.0 and 3.8 hours.Īfter use 14S-UTF a dose of 4.86 mg/kg, the Cmax value, the making 1.291 mg/kg, were reached in 20 minutes. Then radioactivity was quickly removed with elimination half-life 0.5 and 0.6 hours for alpha distribution and beta elimination, respectively.Īfter use 14S-TsMF a dose of 4.83 mg/kg, the Cmax value, the making 1.567 mg/kg, were reached in 20 minutes. The purposes of this research consisted in assessment of absorption and pharmacokinetics of UMF, CMF and also UTF.Īfter use 14S-UMF a dose of 4.97 mg/kg, the maximum concentration in plasma (Cmax) making 1.749 mg/kg were reached in 10 minutes. Pharmacokinetics Components properties of this drug have organic origin which are already present at biological liquids, causes difficulty of carrying out pharmacokinetic researches of drug, and it formed the basis of carrying out a research with use of a product, marked radioactive isotopes.

Nucleo forte capsulas code#

The Code of automatic telephone exchange N07XX Contents of capsules powder of white color, is hygroscopic.ĭrugs for treatment of diseases of nervous system other 2, body of gray color, lid of blue color. Structure of the capsule: ferrous oxide black E172, titan E171 dioxide, gelatin, E132 indigo carmine. Of the Structure One Capsule Capsule containsĪctive agents: cytidine 5 dinatrium monophosphate 5.00, uridine 5 trisodium triphosphate, uridine 5 dinatrium diphosphate, uridine 5 dinatrium monophosphate (only) 3.00 (it is equivalent to uridine content) (1.33).Įxcipients: citric acid, citrate sodium dihydrate, magnesium stearate, silicon dioxide colloidal, Mannitolum.